IXI Ixico Plc

TIDMIXI

RNS Number : 2819F

IXICO plc

16 May 2017

16 May 2017

IXICO plc

("IXICO" or the "Company")

Notice of Interim Results

IXICO, the brain health company, will announce its interim results for the six months ended 31 March 2017 on Monday 22 May 2017.

For further information please contact:

 
 IXICO plc 
  Susan Lowther, Chief Financial Officer     Tel: +44 20 
                                             3763 7499 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield            7408 4090 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan 
 

About IXICO

Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global Pharmaceutical industry to select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis and Parkinson's and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant patient clinical data to enable sponsors to make rapid, better informed decisions.

IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREAPSKFSXXEEF

(END) Dow Jones Newswires

May 16, 2017 04:57 ET (08:57 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024

Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024